AI & Technology

GSK today announced that it has submitted a regulatory application to the European Medicines Agency (EMA) for its antiseptic chlorhexidine gel (7.1% chlorhexidine digluconate gel, equivalent to 4% chlorhexidine) for the prevention of umbilical cord infections (omphalitis) in newborn babies. GSK’s work to develop the gel began in response to a call from the United Nations (UN) in 2012 for manufacturers to make a high quality chlorhexidine product suitable for newborn infants in low resources settings.

What does biomimicry have to do with Green Money? Well, everything. Biomimicry is the conscious emulation of nature’s wisdom, a methodology that is based not on harvesting nature but on learning from nature. This approach is beginning to shape our cities, our companies, and our social sphere, and has profound implications for investing and for life.

The human brain is continuously adapting and evolving. With technology, the digital world enables people to perform virtually all daily activities from the comfort of their homes without seeing another human being. How does this type of evolution impact overall quality of life?

Moving forward and advancing in the world is inevitable. The manual way of doing things is quickly being replaced with technology and with a more superior process. As companies find ways to enhance their capabilities in their global markets, they are quickly identifying what solutions are making their processes, with regard to world wide regulatory compliance, a much more manageable and streamlined practice.

Late last month the United Nations approved the Goals for Sustainable Development (SDGs), the most comprehensive and ambitious set of 17 goals to end poverty, fight inequality and injustice, and tackle climate change by 2030. But to achieve these goals it's going to take a village, or rather an entire planet, to succeed.